- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Munich-based NascaCell Technologies AG and Capsulution Nanoscience AG, Berlin, signed a joint development and license option agreement. As part of this joint development program, NascaCell as leading provider of customized aptamers and Microbodies™ and Capsulution, an internationally renowned developer of nano-complexes and -capsules, will develop innovative solutions for improved delivery of aptamers and other nucleic acids into cells. The joint development will benefit from the combination of advanced nano-technologies and efficient transport peptides and will generate innovative, target-specific delivery systems for biomolecules into cells and experimental animals.
Specifically, the partners will couple aptamers to functional peptide nanoparticles with subsequent analyses in cellular assays as well as animal studies. The nano-particles and -capsules are also suitable to deliver drug development candidates and will be optimized in this direction.
"We expect additional growth of our aptamer service business, in particular for intracellular applications, from this combination of our gene transfer know how and Capsulution's established formulation expertise. Furthermore, these new methods will also be applicable for other applications such as therapeutic RNAi. Capsulution with an established track record of its innovative technology is an ideal partner in this endeavour, " says Dr. Ernst Boehnlein, CEO of NascaCell.
In addition to the application of its technologies by its partner, Capsulution expects gain of additional know how. "NascaCell has a unique experience in the areas of target validation and drug discovery from which we can benefit in the development of custom-tailored solutions," says Alexander Herrmann, CFO of Capsulution.
About Capsulution NanoScience AG
Capsulution NanoScience AG is a leading nanotechnology company focusing on the development of tailor-made drug delivery systems and other innovative life science products based on tunable nano-sized capsules. The company applies its worldwide-patented so-called LBL-Technology®. Based on their minute size, their functionality and their highly reproducible production process the tunable capsules can be used for a multitude of different applications. Accordingly, the precisely sized capsules can be made to function in a manner to suit the intended application, and can be given the appropriate biochemical, electrical, optical and magnetic properties as required by the customer.
About NascaCell Technologies AG - www.nascacell.com
NascaCell Technologies AG, based in Munich, is a global leading provider of a new generation of biomolecules. With the innovative Aptamer and MicrobodyTM technologies, the company supports customers in the target validation and drug discovery R&D areas. NascaCell also develops a line of products and drug development candidates based on the MicrobodyTM technology.
For more information, please click here
Copyright © Capsulution NanoScience AGIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Simple attraction: Researchers control protein release from nanoparticles without encapsulation: U of T Engineering discovery stands to improve reliability and fabrication process for treatments to conditions such as spinal cord damage and stroke May 28th, 2016
The next generation of carbon monoxide nanosensors May 26th, 2016
Revealing the nature of magnetic interactions in manganese oxide: New technique for probing local magnetic interactions confirms 'superexchange' model that explains how the material gets its long-range magnetic order May 25th, 2016